Personalis shares rose after the company received Medicare coverage for its NeXT Personal molecular residual disease test for surveillance of patients with Stage I to III non-small cell lung cancer.

Investing.com -- Personalis Inc (NASDAQ:PSNL) stock jumped 9.3% Tuesday after the precision oncology company announced ...

Personalis, Inc. , a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company's NeXT Personal molecular residual disease (MRD) test for surveillance of ...

Personalis, Inc. PSNL stock is up in Tuesday’s premarket session after the company received Medicare coverage for its NeXT ...

NCCN's newly updated NSCLC guidelines add sevabertinib as a treatment option and datopotamab deruxtecan-dlink a potential preferred option.

Medicare will reimburse the company’s NeXT Personal molecular residual disease (MRD) test when used to monitor patients with ...

Lung cancer remains one of the leading causes of cancer-related deaths globally and in India; yet it is also one of the most misunderstood cancers. Public perception has long framed it as a ...

Lung cancer is one of the leading causes of cancer-related death in our country, especially due to widespread myths and the lack of awareness.

Comprehensive biomarker testing is crucial for NSCLC treatment, yet disparities exist between academic and community settings ...

Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary ...

This is a "landmark study" for cancer immunotherapy and circadian medicine, researcher say ...